In the Margins
French pharmaceutical company Sanofi said it will seek to replace the board of Medivation after the American drug maker’s directors rejected a $9.3 billion takeover offer. Sanofi said in April that Medivation’s directors had failed to respond to its approach. Meanwhile, Medivation’s board called the offer “inadequate,” and founder and CEO David Hung has said the French company’s move was “opportunistically timed.” Read the original story from The New York Times.
Most Read
Richard Redeker has seen a lot in his 50 years in the mutual fund business, half of which he's spent as an independent director of what ...
As part of their larger risk oversight role, mutual fund boards are increasingly considering their role in evaluating “culture risk” and how it relates to sexual ...
As the end of the year approaches, there are several issues that are likely to come up for discussion between chief compliance officers and mutual fund ...
Independent mutual fund directors are required to assess the reasonableness of the profits the management company earns from its advisory contract. It’s a challenging task, since ...